Zura Bio keeps 2028 cash runway ahead of year‑end tibulizumab data
US$187.7M in cash supports planned operations as two fully enrolled autoimmune trials approach readouts and a third study awaits its start.
Adrian Kessler
A US$187.7 million cash balance at Sept. 30 is expected to fund operations through at least 2028 as Zura Bio Limited NASDAQZURA said in its Tuesday update. Management expects the balance to cover results from all three tibulizumab studies, with the first Phase 2 readout due in the fourth quarter.
Cash was down from US$205.1 million at June 30, while the funding horizon was unchanged from Zura's Aug. 11 update. The third-quarter net loss widened to US$25.8 million from US$20 million a year earlier, as spending rose on its lead antibody's development.
Zura is a small clinical-stage immunology developer based in Henderson, Nevada, building dual-pathway antibodies for autoimmune and inflammatory diseases.
Shares NASDAQZURA closed at US$3.56 on Nasdaq at 4:00 p.m. EDT on Oct. 26. That close preceded Tuesday's results and provides no measure of the market's response to the announcement.
Two Fully Enrolled Trials Approach Readouts
Tibulizumab is designed to neutralize interleukin-17 and B-cell activating factor, targeting two immune pathways with one antibody. Zura's trial information describes both ongoing studies as randomized and placebo-controlled; neither has reported its upcoming efficacy results in Tuesday's update.
TibuSHIELD enrolled 247 adults with hidradenitis suppurativa. Its fourth-quarter results will include the primary endpoint, percentage change from baseline in total abscess and inflammatory nodule count at week 16, alongside clinical response measures.
TibuSURE enrolled 91 adults with early diffuse cutaneous systemic sclerosis, with topline data expected in the first half of 2027. Its primary endpoint measures the change in modified Rodnan Skin Score at week 24, with lung-involvement measures also planned.
The FDA has cleared the investigational new drug application for NEXUS-PMR to proceed, according to Zura. The Phase 2 polymyalgia rheumatica study remains scheduled to begin by year-end; permission to test the antibody does not establish safety or efficacy.
Research and development expense rose to US$19.5 million in the third quarter of 2026 from US$11.9 million a year earlier. Zura attributed the increase to execution of its ongoing tibulizumab trials and start-up work for NEXUS-PMR.
"With cash runway sufficient to deliver results from all three studies, Zura is in a great position to deliver on tibulizumab’s unique potential," co-founder and chief executive Sandeep Kulkarni said in the release.
Tibulizumab remains investigational and has no marketing approval. Tuesday's update supplied no new trial safety results, leaving tolerability alongside efficacy to be assessed when the studies report.
Cash Horizons Differ Across Clinical Developers
The iShares Biotechnology ETF NASDAQIBB closed at US$208.69 at 4:00 p.m. EDT on Oct. 26, providing a dated sector benchmark ahead of Zura's announcement.
Among autoimmune developers, Climb Bio, Inc. NASDAQCLYM reported US$239.2 million in cash, equivalents and marketable securities at June 30. Its Aug. 6 update forecast funding into the second half of 2028 for a pipeline including budoprutug, an antibody targeting CD19.
Read more: Climb Bio reports 38 per cent immunologic remission in kidney trial
Elsewhere in clinical development, Fractyl Health, Inc. NASDAQGUTS announced on Oct. 22 that it would cut approximately 45 per cent of its workforce. Its revised operating plan projects cash lasting into the second quarter of 2027, illustrating how spending decisions shape the period available to reach milestones.
Read more: Fractyl Health plans 45 per cent job cut to fund Revita FDA submission
Zura's next scheduled clinical test is the fourth-quarter TibuSHIELD readout, which will show whether tibulizumab improves the study's inflammatory-lesion endpoint against placebo.
